tarlatamab,BI 764532
amgen,Boehringer Ingelheim
['tarlatamab', 'sclc']
encouraging efficacy for bi 764532 in #sclc at #asco23. rr 26% in sclc, 19% in extra pulmonary small cell, and 3/5 in lcnec. durability see. (median not reached). new entry to the field joins tarlatamab and looks very promising. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo